Neuphoria Therapeutics Inc.$7.97 %
Analyst Rating: Hold
Stock Details
CEO
Spyridon Papapetropoulos
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Full Time Employees
8
Address
100 Summit Dr, Burlington
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Top Competitors
Income Statement
Financials
Selected Year
Revenue Estimates
EPS Estimates
Net Income Estimates
Price target for Neuphoria Therapeutics Inc. $7.97
$0
Min Forecast(+0% )
$249.61
Avg Forecast( +0% )
$325
Max Forecast(+0%)
EPS
Revenue
Institutional Holder
Loading institutional holder data...
Congress Tracker
Showing 0 of 0 results
Insider Trading of Key Employees
Showing 0 of 0 results